DE60036019D1 - Synthetische oligonukleotide die therapeutisch nützlich sind - Google Patents

Synthetische oligonukleotide die therapeutisch nützlich sind

Info

Publication number
DE60036019D1
DE60036019D1 DE60036019T DE60036019T DE60036019D1 DE 60036019 D1 DE60036019 D1 DE 60036019D1 DE 60036019 T DE60036019 T DE 60036019T DE 60036019 T DE60036019 T DE 60036019T DE 60036019 D1 DE60036019 D1 DE 60036019D1
Authority
DE
Germany
Prior art keywords
synthetic oligonucleotides
therapeutically useful
induction
group
caspases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036019T
Other languages
English (en)
Other versions
DE60036019T2 (de
Inventor
Nigel C Phillips
Mario C Filion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telesta Therapeutics Inc
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of DE60036019D1 publication Critical patent/DE60036019D1/de
Publication of DE60036019T2 publication Critical patent/DE60036019T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
DE60036019T 1999-12-13 2000-12-12 Synthetische oligonukleotide die therapeutisch nützlich sind Expired - Lifetime DE60036019T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17032599P 1999-12-13 1999-12-13
US170325P 1999-12-13
US22892500P 2000-08-29 2000-08-29
US228925P 2000-08-29
PCT/CA2000/001467 WO2001044465A2 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides

Publications (2)

Publication Number Publication Date
DE60036019D1 true DE60036019D1 (de) 2007-09-27
DE60036019T2 DE60036019T2 (de) 2008-05-29

Family

ID=26865979

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60043759T Expired - Lifetime DE60043759D1 (de) 1999-12-13 2000-12-12 Therapeutisch nützliche synthetische Oligonukleotide
DE60036019T Expired - Lifetime DE60036019T2 (de) 1999-12-13 2000-12-12 Synthetische oligonukleotide die therapeutisch nützlich sind

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60043759T Expired - Lifetime DE60043759D1 (de) 1999-12-13 2000-12-12 Therapeutisch nützliche synthetische Oligonukleotide

Country Status (18)

Country Link
US (2) US7157436B2 (de)
EP (2) EP1238070B1 (de)
JP (1) JP4772245B2 (de)
KR (1) KR100829646B1 (de)
CN (2) CN100445380C (de)
AT (2) ATE455851T1 (de)
AU (1) AU785212B2 (de)
CA (1) CA2393808A1 (de)
CZ (1) CZ20022372A3 (de)
DE (2) DE60043759D1 (de)
DK (2) DK1867718T3 (de)
ES (2) ES2340807T3 (de)
HU (1) HUP0300627A3 (de)
IL (2) IL150196A0 (de)
MX (1) MXPA02005842A (de)
NO (1) NO330508B1 (de)
PT (1) PT1238070E (de)
WO (1) WO2001044465A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
ATE375358T1 (de) 1999-04-08 2007-10-15 Antisoma Res Ltd Antiproliferative aktivität von g-reichen oligonukleotiden und verfahren um sie zur bindung an nukleotin zu verwenden
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
ES2340807T3 (es) * 1999-12-13 2010-06-09 Bioniche Life Sciences Inc. Oligonucleotidos sinteticos utiles terapeuticamente.
AU6886301A (en) 2000-08-29 2002-03-13 Bioniche Life Sciences Inc Modulation of fas and fasl expression
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
ATE428781T1 (de) 2001-08-17 2009-05-15 Bioniche Life Sciences Inc Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose
ATE314096T1 (de) 2001-10-03 2006-01-15 Bioniche Life Sciences Inc Therapeutisch verwendbare triethylenglykol- cholesteryl-oligonukleotide
CA2483012C (en) 2002-04-22 2011-05-24 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
CA2521050A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
EP1628531A4 (de) * 2003-05-16 2010-06-30 Idera Pharmaceuticals Inc Synergistische behandlung von krebs durch gemeinsame verwendung von immunomeren und chemotherapeutika
AU2006216493A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
WO2006099021A2 (en) * 2005-03-09 2006-09-21 Baylor College Of Medicine Direct reversal of the suppressive function of cd4+ regulatory t cells via toll-like receptor 8 signaling
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
CN102439149B (zh) * 2009-02-12 2018-01-02 库尔纳公司 通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
US9040493B2 (en) * 2009-07-15 2015-05-26 Santaris Pharma A/S RNA antagonists targeting GLI2 for the treatment of leukemia
US20150045248A1 (en) * 2012-02-28 2015-02-12 National University Corporation Tokyo University Of Agriculture And Technology Method for identifying disease associated with abundance of tdp-43 in cell
EP4000597A1 (de) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptid und zusammensetzungen mit tetrapeptiden
WO2023122762A1 (en) * 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (de) * 1971-11-19 1975-02-07 Anvar
CA1020460A (en) * 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) * 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DE3723075A1 (de) * 1987-07-11 1989-01-19 Boehringer Mannheim Gmbh Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
AU1456092A (en) * 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
EP0952855B1 (de) * 1991-07-03 2005-07-27 Meditech Research Limited Verwendung von hyaluronan in gentherapie
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
JPH08508976A (ja) * 1993-01-29 1996-09-24 ベトレフアーム・インコーポレーテツド 改善化免疫療法用組成物
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CN1154702A (zh) * 1994-05-25 1997-07-16 海布里登公司 具有抗巨细胞病毒活性的寡核苷酸
NZ291734A (en) * 1994-08-30 1997-09-22 Commw Scient Ind Res Org Plant transcription regulators from circovirus; isolated nucleic acid molecules and transgenic plants
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN181358B (de) * 1995-02-14 1998-05-30 Bioniche Inc
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
CA2236825A1 (en) * 1995-11-21 1997-05-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
IT1277025B1 (it) * 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
DE69738454D1 (de) * 1996-05-20 2008-02-21 Us Gov Health & Human Serv Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
IL134371A0 (en) * 1997-08-05 2001-04-30 Bioniche Life Sciences Inc Composition and method for regulating cell proliferation and cell death
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
EP1700603A3 (de) * 1999-09-25 2007-06-13 Coley Pharmaceutical GmbH Immunstimmulierende Nukleinsäuren
ES2340807T3 (es) * 1999-12-13 2010-06-09 Bioniche Life Sciences Inc. Oligonucleotidos sinteticos utiles terapeuticamente.
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
US7125858B2 (en) * 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
ATE314096T1 (de) * 2001-10-03 2006-01-15 Bioniche Life Sciences Inc Therapeutisch verwendbare triethylenglykol- cholesteryl-oligonukleotide
CA2483012C (en) * 2002-04-22 2011-05-24 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses

Also Published As

Publication number Publication date
IL150196A0 (en) 2002-12-01
CZ20022372A3 (cs) 2002-11-13
HUP0300627A2 (hu) 2004-06-28
US20070213291A1 (en) 2007-09-13
AU1847901A (en) 2001-06-25
ES2288883T3 (es) 2008-02-01
ES2340807T3 (es) 2010-06-09
JP4772245B2 (ja) 2011-09-14
EP1867718B1 (de) 2010-01-20
KR20020079752A (ko) 2002-10-19
CN101491536A (zh) 2009-07-29
HUP0300627A3 (en) 2005-11-28
ATE370231T1 (de) 2007-09-15
CN100445380C (zh) 2008-12-24
EP1867718A3 (de) 2008-04-02
CN1433469A (zh) 2003-07-30
WO2001044465A2 (en) 2001-06-21
PT1238070E (pt) 2007-11-06
NO20022820L (no) 2002-08-08
AU785212B2 (en) 2006-11-09
DE60036019T2 (de) 2008-05-29
KR100829646B1 (ko) 2008-05-16
WO2001044465A3 (en) 2001-11-29
EP1238070B1 (de) 2007-08-15
EP1238070A2 (de) 2002-09-11
NO20022820D0 (no) 2002-06-13
EP1867718A2 (de) 2007-12-19
NO330508B1 (no) 2011-05-09
CA2393808A1 (en) 2001-06-21
ATE455851T1 (de) 2010-02-15
US20010041681A1 (en) 2001-11-15
DK1238070T3 (da) 2007-12-03
IL150196A (en) 2009-06-15
MXPA02005842A (es) 2003-10-14
DK1867718T3 (da) 2010-04-12
US7157436B2 (en) 2007-01-02
CN101491536B (zh) 2012-07-04
JP2003517041A (ja) 2003-05-20
DE60043759D1 (de) 2010-03-11

Similar Documents

Publication Publication Date Title
ATE370231T1 (de) Synthetische oligonukleotide die therapeutisch nützlich sind
EP0666923A4 (de) Gezielte bereitstellung von poly- oder oligonukleotiden in zellen.
GB2363874B (en) Bioinformatic transaction scheme
HK1048642A1 (en) Fap-activated anti-tumor compounds.
EP0659209A4 (de) Krebstherapie unter verwendung maligner zellen.
HUP0302345A3 (en) Novel triazolo pyrimidine compounds, their intermediates and process for their preparation
ZA200006039B (en) Novel nucleotide sequences coding for the poxB gene.
WO2002036601A3 (en) Phase transfer catalyzed glycosidation of an indolocarbazole
AU7720800A (en) Engineered radiation resistant bioremediating bacteria
GB9807114D0 (en) Novel process
HK1041598A1 (en) Formulation with an improved therapeutic range, containing nucleotide synthesis in hibitors.
GB9920816D0 (en) Plant gene
PH31659A (en) Therapeutic nucleotides.
HUT76968A (hu) Új topoizomeráz IV, ezt kódoló nukleotid szekvenciák és az enzim felhasználása
ZA962066B (en) Preparation of 4,6-dimethoxy-2-(phenoxycarbonyl)amino-pyrimidine.
GB9917109D0 (en) Plant genes
GB0026844D0 (en) Process and intermediates to a tetrahydro-[1,8]-naphthyridine
EP1231266A4 (de) Gdp-4-keto-6-deoxy-d-mannose-3,5-epimerase-4-reduktasegene aus arabidopsis
GB9914600D0 (en) Novel,process
ITMI920892A1 (it) Selezione genica in vitro mediante vettori ad rna
GB9921938D0 (en) Target for antiviral therapy
CA2103062A1 (en) Oligo-2'-deoxynucleotides and their use as pharmaceutical agents with antiviral activity
GB0407474D0 (en) Bioinformatic transaction scheme
ITMI911430A1 (it) Composizione vetrosa ceramizzabile adatta per il rivestimento di manufatti ceramici, in particolare piastrelle.
ITMI991513A0 (it) Piastra radiante per panificazione

Legal Events

Date Code Title Description
8364 No opposition during term of opposition